Calgary, Alberta – January 7, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company...
Calgary, Alberta – November 26, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share additional data from its ongoing preclinical Rett syndrome...
Calgary, Alberta – November 21, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it has been awarded the Alberta Innovates AICE...
CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) – Marvel Biosciences Corp.(TSX:V MBCOF:OTC), based in Calgary, Alberta, focused on Alzheimer’s Disease, Depression and Autism today announced that Dr. Mark Williams, CSO will present live at the Life Sciences...
Calgary, Alberta – November 7, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB204, as a...
Calgary, Alberta – October 10, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today shared promising results from a recent study on MB204. The research was...
